whatshot

IPHYF   $2.91  -3.00% Market Closed

INNATE PHARMA
show_chart Advanced Chart of IPHYF
Last Events:

2023-07-18 Signal in MACD changed from bearish to bullish. Oscillator MACD is in the positive territory it's higher than the signal line and grows. These factors mean that positive mood prevails. Last signal: main and signal line crossing.

2023-07-18 Signal in RSI changed from bearish weakening to bullish recovery. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: exit from the overbought zone.

2023-07-18 Signal in EMA50 changed from bearish reversal to bullish reversal. 2023-06-08 the price crossed up the moving average line and formed a short-term upside trend.

2023-07-18 Signal in EMA20 changed from bearish reversal to bullish reversal. 2023-06-08 the price crossed up the moving average line and trying to form a short-term upside trend.

2023-07-18 Trend Power changed from slow to almost flat.

2023-07-18 Trend changed from linear down to down and flat.

2023-05-11 Trend pattern changed from расширяющаяся формация to сужающийся канал.

2023-05-06 Signal in Stochastic changed from bearish weakening to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 5
Target Price Mean 6
Mean unverified/preliminary 6 / 6
Target Price Low / High 3 / 10
Median / STD DEV 7 / 2.41
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total - Sell Sell
rsi ActivelyBuy Sell -
macd - - -
stoch - - -
ma20 ActivelyBuy Sell Sell
ma50 Sell - -
ma100 Sell Sell -
Candlestick PatternMarch 3, 2023 Rickshaw - is a long candlestick with a doji body. In particular, the rickshaw man is a type of long legged doji where the body must be located at or very near the middle of the candle. Indicates indecision in the market.
ISIN FR0010331421
ceo Mr. Jonathan E. Dickinson
Website https://www.innate-pharma.com
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.